$96.94
0.82% today
Nasdaq, Nov 12, 08:44 pm CET
ISIN
US6707031075
Symbol
NUVL

Nuvalent Inc - Ordinary Shares - Class A Stock price

$96.16
+6.41 7.14% 1M
+22.53 30.59% 6M
+17.88 22.83% YTD
+1.77 1.87% 1Y
+64.16 200.48% 3Y
+77.41 412.83% 5Y
+77.41 412.83% 10Y
+77.41 412.83% 20Y
Nasdaq, Closing price Tue, Nov 11 2025
+3.18 3.41%
ISIN
US6707031075
Symbol
NUVL
Industry

Key metrics

Basic
Market capitalization
$7.0b
Enterprise Value
$6.0b
Net debt
positive
Cash
$943.1m
Shares outstanding
72.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
8.3
Financial Health
Equity Ratio
93.7%
Return on Equity
-24.4%
ROCE
-44.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-399.2m
EBIT
$-398.4m | $-423.7m
Net Income
$-381.4m | $-418.4m
Free Cash Flow
$-263.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-65.6% | -51.1%
Net Income
-70.1% | -60.5%
Free Cash Flow
-72.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-5.3
FCF per Share
$-3.7
Short interest
15.5%
Employees
200
Rev per Employee
$0.0
Show more

Is Nuvalent Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.

Nuvalent Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

21x Buy
95%
1x Hold
5%

Analyst Opinions

22 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

Buy
95%
Hold
5%

Financial data from Nuvalent Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 90 90
59% 59%
-
- Research and Development Expense 309 309
68% 68%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -398 -398
66% 66%
-
Net Profit -381 -381
70% 70%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nuvalent Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nuvalent Inc - Ordinary Shares - Class A Stock News

Positive
Seeking Alpha
8 days ago
NUVL is approaching the precipice of a first targeted therapy approval in lung cancer. They also have an increasingly deep pipeline of therapies, with an audacious phase 3 trial spinning up in ALK-positive NSCLC. Cash position remains strong as well, but the market is pricing in too much success for me to be comfortable at this time.
Neutral
PRNewsWire
8 days ago
Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session CAMBRIDGE, Mass. , Nov. 4, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the first presentation of patient-reported outcomes data...
Neutral
PRNewsWire
13 days ago
Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC On track to report topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC by year-end 2025 Strong financial position with operating runway anticipated into 2028 CAMBRIDGE, Mass. , Oct. 30, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceut...
More Nuvalent Inc - Ordinary Shares - Class A News

Company Profile

Nuvalent, Inc. operates as a preclinical stage biopharmaceutical company. The company creates precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Its focus its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. The company was founded in January 2017 and is headquartered Cambridge, MA.

Head office United States
CEO James Porter
Employees 200
Founded 2017
Website www.nuvalent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today